Nanotechnology Now

Our NanoNews Digest Sponsors

Heifer International

Wikipedia Affiliate Button

Home > Press > BioSante Pharmaceuticals to Present at Upcoming Conferences

Abstract:
Noble Financial TWO DOUBLE-O-SEVEN Equity Conference

BioSante Pharmaceuticals to Present at Upcoming Conferences

LINCOLNSHIRE, IL | Posted on August 8th, 2007

BioSante Pharmaceuticals (AMEX: BPA) today announced that BioSante management will present a corporate overview and update at upcoming conferences. The conferences are:

* The Flaherty Financial News & Wall Street Research Small Cap Conference on August 14, 2007 at 10:20 a.m. local time at the Penn Club of New York.
* The RedChip Small-Cap Investor Conference on August 16, 2007 at 11:00 a.m. and the Keynote address at 12:30 p.m. local time at the Waldorf-Astoria Hotel New York.
* The Noble Financial TWO DOUBLE-O-SEVEN conference on August 20, 2007 at 1:00 p.m. local time at the Orient Express Hotel in Charleston, South Carolina.

A live audio webcast of BioSante's presentation at the RedChip and Noble conferences can be accessed on the internet by visiting http://www.biosantepharma.com . An archive of these presentations will be available at the same address.

These conferences each feature companies presenting to a diverse group of investors, portfolio managers and analysts interested in the biotechnology and pharmaceuticals sectors as well as industry representatives.

####

About BioSante Pharmaceuticals
BioSante is developing a pipeline of hormone therapy products to treat both men and women. These hormone therapy products are gel formulations for transdermal administration that deliver bio-identical estradiol and testosterone. BioSante's lead products include Elestrin™ (estradiol gel) developed through FDA approval by BioSante indicated for the treatment of moderate-to-severe vasomotor symptoms associated with menopause, marketed in the U.S. by Bradley Pharmaceuticals, Inc., BioSante's licensee, and LibiGel® (transdermal testosterone gel) in Phase III clinical development by BioSante for the treatment of female sexual dysfunction (FSD). Also in development is Bio-T-Gel™, a testosterone gel for male hypogonadism, and an oral contraceptive in Phase II clinical development using BioSante patented technology. The current market in the U.S. for estrogen and testosterone products is approximately $2.5 billion and for oral contraceptives approximately $3.0 billion. The company also is developing its calcium phosphate nanotechnology (CaP) for novel vaccines, including hepatitis B, avian flu and biodefense vaccines for toxins such as anthrax, as well as a system for delivering drugs via alternative routes of administration and for aesthetic medicine.

For more information, please click here

Contacts:
BioSante Pharmaceuticals, Inc.
Phillip Donenberg
(847) 478-0500

Copyright © Business Wire 2007

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

Nanomedicine

Nanoparticle vaccine shows potential as immunotherapy to fight multiple cancer types April 24th, 2017

Arrowhead Presents ARC-520 and ARC-521 Clinical Data at The International Liver Congress(TM) April 20th, 2017

Nano-SPEARs gently measure electrical signals in small animals: Rice University's tiny needles simplify data gathering to probe diseases, test drugs April 17th, 2017

Nanotubes that build themselves April 14th, 2017

Announcements

Geoffrey Beach: Drawn to explore magnetism: Materials researcher is working on the magnetic memory of the future April 25th, 2017

Using light to propel water : With new method, MIT engineers can control and separate fluids on a surface using only visible light April 25th, 2017

Graphene holds up under high pressure: Used in filtration membranes, ultrathin material could help make desalination more productive April 24th, 2017

Nanoparticle vaccine shows potential as immunotherapy to fight multiple cancer types April 24th, 2017

Events/Classes

National Conference on Nanomaterials, (NCN-2017) April 21st, 2017

Nanomechanics, Inc. Unveils New Product at ICMCTF Show April 25th: Nanoindentation experts will launch the new Gemini that measures the interaction of two objects that are sliding across each other – not merely making contact April 21st, 2017

Forge Nano 2017: 1st Quarter Media Update April 20th, 2017

Arrowhead Presents ARC-520 and ARC-521 Clinical Data at The International Liver Congress(TM) April 20th, 2017

NanoNews-Digest
The latest news from around the world, FREE



  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project